source
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
- Oura announces acquisition of Counsel Health at HLTH conferenceOura, known for its wearable health tracker, disclosed that it is purchasing Counsel Health, a company that provides health data services. The announcement was made during the HLTH conference, whe…